



ASX ANNOUNCEMENT

2 March 2022

## Mobvoi launches TicWatch GTH Pro

*World's first consumer wearable device to feature ATCOR heart health technology*

### Highlights:

- **Mobvoi, a leading global consumer electronics and enterprise AI developer, has officially launched a new consumer smartwatch, the TicWatch GTH Pro, with advanced heart health features powered by CardieX subsidiary ATCOR.**
- **The TicWatch GTH Pro includes ATCOR's proprietary Arty™ Heart Health analytics platform, which is an advanced heart and arterial health management platform based on ATCOR's FDA-cleared SphygmoCor® technology.**
- **The TicWatch GTH Pro launch represents the first commercial implementation of ATCOR's proprietary heart monitoring technology in a wearable device.**

CardieX Limited (ASX:CDX) (**CardieX, the Company**) is pleased to announce the official commercial launch of the world's first heart health monitoring smartwatch to feature ATCOR heart health technology through its commercial partnership with Mobvoi (as announced 24 September 2020), a leading consumer electronics and enterprise AI developer.

The TicWatch GTH Pro was launched on 1 March 2022 via Mobvoi.com, Amazon, and GTHPro.com for customers in the United States.

Pre-order is available for customers from Australia and New Zealand on Amazon and Mobvoi.com.

The TicWatch GTH Pro is the world's first consumer device to feature unique and proprietary heart health features powered by CardieX subsidiary, ATCOR.

### ***Product Development & Core Watch Features***

The TicWatch GTH Pro is the result of a two-year co-development partnership between Mobvoi and CardieX to develop a new consumer smartwatch under the Mobvoi brand based on CardieX subsidiary, ATCOR's proprietary and FDA approved SphygmoCor® technology.

Hardware and firmware development has been led by Mobvoi and was focused on the integration of a unique set of 'Arty Heart Health' algorithms that give users deep insights into their arterial and overall heart health.

**'Arty Heart Health powered by ATCOR'** non-invasively measures "central arterial waveforms", which are pressure waves based on the strength of the pulse as blood flows through the body.



The TicWatch GTH Pro utilizes unique “dual PPG sensors” to provide insights into arterial health through high-fidelity sensing points that track both from the wrist and by way of a special PPG finger sensor. The data gathered from the watch appears on the Mobvoi app and the Arty Heart Health platform compiles the metrics into five key points of heart health analysis.

Combined with Mobvoi’s own smartwatch metrics, the Arty Heart Health platform gives users easy-to-understand insights into their overall wellness and cardiovascular health.

**The Arty Heart Health platform includes:**

- **Arty Score** – a general score on overall heart and arterial health;
- **eCAP™** (Exercise Capacity™) – which is a measure of healthy blood flow to the heart muscles;
- **ArtyAge™** – an estimated “age” of the arteries based on arterial stiffness;
- **HSX™** (Heart Stress Index) – a measure of stress on the heart; and
- **TruHR™** – a highly accurate medical grade<sup>1</sup> heart rate measurement similar to an electrocardiogram.

All the above parameters are based upon ATCOR’s FDA-cleared SphygmoCor® technology.

**CardieX CEO and Managing Director, Craig Cooper, commented:**

*“I am excited to finally announce the official launch and availability of the TicWatch GTH Pro.*

*This is the first integration of our market leading SphygmoCor® heart health technology into a wearable device and has been the result of a significant two-year collaboration with Mobvoi.*

*Our “Arty Heart Health” platform incorporates unique arterial biometrics and heart health insights based on the 20-year legacy of our ATCOR subsidiary in partnering with global research organizations, pharmaceutical companies, and leading clinical practices. It’s this same trusted, clinical grade technology that we are now incorporating into a series of new consumer wearables and home health devices.*

---

<sup>1</sup> Medical grade Heart Rate (“HR”) requires accurate detection of cardiac pulse duration by precisely identifying the start and the end of the pulse. The accurate detection can be made from Electrocardiograph signal or from recording cardiac pulse as in the FDA cleared SphygmoCor® technology. The “TruHR” parameter has the same medical grade definition of HR and is based on SphygmoCor® medical technology



*Cardiovascular disease remains the world's number one killer<sup>2</sup>. It's our vision and mission to provide advanced heart health metrics into the hands of consumers so that they may have better tools and insights to manage and prevent disease.*

*Ultimately, the more accurate the data you have, the more informed you are to make decisions about your health.*

*The TicWatch GTH Pro is the first in a number of new consumer product releases planned for this year as we continue to move forward with the development, FDA clearance process, and launch of a suite of new wearable and home health devices and apps under our new CONNEQT brand."*

**Carol Wu, Vice President of Mobvoi commented:**

*"With the decrease of health that we saw in the past two years from the pandemic, heart health remains a top issue for healthcare providers.*

*Partnering with CardieX to introduce state-of-the-art heart health monitoring technology to our line of TicWatches is one way to achieve our mission of providing innovative and modern ways to track health and look good doing it."*

Approved by the Board of Directors and Released by Jarrod White, Director.

For more information, please contact:

**Investor Relations**

Rod Hinchcliffe

[rod.hinchcliffe@mcpartners.com.au](mailto:rod.hinchcliffe@mcpartners.com.au)

**Media Relations**

Melissa Hamilton

[melissa.hamilton@mcpartners.com.au](mailto:melissa.hamilton@mcpartners.com.au)

**Investor Relations – USA**

Matt Selinger

Managing Director

Integrus Communications

[mselinger@integcom.com](mailto:mselinger@integcom.com)

---

<sup>2</sup> [https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab\\_1](https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1)



### **About CardieX**

Global health technology company CardieX is a leader in heart health technology and arterial data analysis. Its subsidiary ATCOR is a world leader in medical devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders, with ATCOR's SphygmoCor® technology recognized as the industry standard for measuring central arterial pressure waveforms. CardieX's CONNEQT subsidiary develops and markets consumer home health devices and wearables. CardieX is listed on the Australian Stock Exchange (ASX:CDX).

### **About Mobvoi**

Mobvoi is an innovative AI tech company with in-house core technologies in the areas including speech recognition, natural language understanding, vertical search, etc. Their core consumer products include the TicWatch line of smartwatches and TicPods and Mobvoi Earbuds line of hearables. The Beijing-based Chinese startup has announced six rounds of financing, including Sequoia, Zhenfund, SIG, Google and Volkswagen Group.

Mobvoi formed strategic partnerships with Wear OS by Google in 2015 and with automobile giant Volkswagen in 2017. Mobvoi is dedicated to redefining the next generation of human-machine interaction by bringing hardware/software integrated products into people's daily life with a strong AI-centered approach.